@dr.karanr's Ozempic claims need some fact-checking

What did @dr.karanr actually say?

The surgeon's core argument is that semaglutide is not a short-term fix. He cites a real study showing patients "regained two thirds of the lost weight within a year" of stopping the drug, and argues that for people with serious metabolic disease, the risk-benefit calculation may justify long-term use. For someone chasing a "summer six pack," he says it does not. He also insists lifestyle changes are non-negotiable alongside the medication.

The framing is more nuanced than most TikTok takes on this topic. He is not selling the drug, and he is not dismissing it. He is trying to draw a line between medically appropriate use and cosmetic misuse, which is a legitimate and important distinction that gets lost in a lot of the online conversation around GLP-1 drugs.

Does the science back this up?

Largely, yes. The study he references is real and the numbers are accurate. Wilding et al. (2022, Diabetes, Obesity and Metabolism) followed participants from the original STEP 1 trial after they stopped semaglutide. Within 68 weeks of stopping, participants regained approximately two thirds of the weight they had lost, and cardiometabolic improvements largely reversed. The sample was 327 adults, not quite "almost 2000" as stated, though the broader STEP 1 trial itself enrolled around 1,961 participants.

His point about pancreatitis is also grounded in real pharmacovigilance data. GLP-1 receptor agonists carry a class warning for pancreatitis. The absolute risk is low, but it is not zero, and it is a fair risk to flag for someone who is already metabolically healthy. The comparison to bariatric surgery is also defensible in the literature. Schauer et al. (2017, New England Journal of Medicine) found that for people with obesity and type 2 diabetes, metabolic surgery produced significant remission rates, but the invasiveness and complication profile is objectively higher than subcutaneous injection.

What did they get wrong (or right)?

The sample size slip is worth flagging. Citing "almost 2000 adults" for the regain data conflates the STEP 1 trial enrollment with the withdrawal sub-study, which had a much smaller follow-up cohort. It is not a fabrication, but it is imprecise enough to matter.

He also says semaglutide "can still offer similar weight loss benefits" to surgery. That needs a caveat. For people with severe obesity, bariatric surgery still outperforms GLP-1 agonists in total weight loss magnitude and in long-term durability without ongoing medication. The comparison is not apples to apples.

What he gets right is the clinical logic. The indication for semaglutide under current FDA approval is a BMI of 30 or higher, or 27 or higher with a weight-related comorbidity. Using it to lose a few kilograms for cosmetic reasons is genuinely off-label and exposes low-risk individuals to a side effect profile that is not justified by the benefit. His point about lifestyle modification being necessary is also well-supported. The STEP trials consistently showed that behavioral intervention alongside the drug produced better outcomes than either alone.

What should you actually know?

Semaglutide works while you take it. The regain data is not a reason to dismiss the drug. It is a reason to understand that stopping it without a transition plan is likely to result in weight returning. For people with type 2 diabetes, cardiovascular disease, or clinically defined obesity, that is a strong argument for long-term treatment, not a dealbreaker.

For people who are already at a healthy weight and want to use semaglutide for body composition, the calculus is different. The drug is not approved for that use, the side effect profile includes nausea, vomiting, and rare but serious events like pancreatitis and gastroparesis, and the weight will return when the drug stops. That is not a favorable trade for someone who does not have a metabolic condition driving the need.

The broader point, which this creator makes reasonably well, is that obesity is a chronic disease with biological drivers, not a willpower problem. GLP-1 drugs treat a real pathology. Using them recreationally is a different conversation entirely, and conflating the two does a disservice to patients who genuinely need the medication.